BR112019017560A2 - intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae - Google Patents

intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae Download PDF

Info

Publication number
BR112019017560A2
BR112019017560A2 BR112019017560A BR112019017560A BR112019017560A2 BR 112019017560 A2 BR112019017560 A2 BR 112019017560A2 BR 112019017560 A BR112019017560 A BR 112019017560A BR 112019017560 A BR112019017560 A BR 112019017560A BR 112019017560 A2 BR112019017560 A2 BR 112019017560A2
Authority
BR
Brazil
Prior art keywords
polysaccharide
serotypes
protein
fact
immunogenic composition
Prior art date
Application number
BR112019017560A
Other languages
English (en)
Portuguese (pt)
Inventor
Lancaster Catherine
ABEYGUNAWARDANA Chitrananda
WEN Emily
Pujar Hari
He Jian
E Macnair John
Michael Williams John
G Joyce Joseph
M Skinner Julie
Musey Luwy
A Winters Michael
Mchugh Patrick
J Smith William
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112019017560A2 publication Critical patent/BR112019017560A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112019017560A 2017-02-24 2018-02-20 intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae BR112019017560A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762463216P 2017-02-24 2017-02-24
US201762555444P 2017-09-07 2017-09-07
PCT/US2018/018729 WO2018156491A1 (en) 2017-02-24 2018-02-20 Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates

Publications (1)

Publication Number Publication Date
BR112019017560A2 true BR112019017560A2 (pt) 2020-04-07

Family

ID=63254065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019017560A BR112019017560A2 (pt) 2017-02-24 2018-02-20 intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae

Country Status (10)

Country Link
US (4) US11090374B2 (cg-RX-API-DMAC7.html)
EP (1) EP3589314A4 (cg-RX-API-DMAC7.html)
JP (3) JP7680185B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240011879A (cg-RX-API-DMAC7.html)
CN (1) CN110337307A (cg-RX-API-DMAC7.html)
AU (1) AU2018225099B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019017560A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050120A1 (cg-RX-API-DMAC7.html)
MX (3) MX2019009867A (cg-RX-API-DMAC7.html)
WO (1) WO2018156491A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308456A (en) * 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
CN110225757A (zh) * 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
WO2019050818A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074706A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
EP3720483B1 (en) 2017-12-06 2025-11-19 Merck Sharp & Dohme LLC Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
WO2019212846A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
MX2021003358A (es) * 2018-09-23 2021-05-27 Biological E Ltd Polisacaridos capsulares purificados de streptococcus pneumoniae.
EP3897705A2 (en) * 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20220184199A1 (en) * 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA3142692A1 (en) * 2019-06-05 2020-12-10 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
KR20220146451A (ko) * 2020-01-17 2022-11-01 인벤트프라이즈 엘엘씨 다가 스트렙토코커스 백신
EP4101192A4 (en) * 2020-02-03 2024-02-28 Anagog Ltd. DELIVERY OF DISTRIBUTED CONTENT
ES2984813T3 (es) * 2020-04-28 2024-10-31 Janssen Pharmaceuticals Inc Método para la identificación y la cuantificación de polisacáridos en composiciones de glicoconjugados complejas
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) * 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法
US20260098841A1 (en) * 2022-09-16 2026-04-09 Merck Sharp & Dohme Llc Method for quantification of polysaccharide content in conjugate vaccines
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025219904A1 (en) * 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PL1866342T3 (pl) 2005-04-08 2019-04-30 Wyeth Llc Oddzielanie zanieczyszczeń od polisacharydu Streptococcus pneumoniae przez manipulację pH
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
CA2665169C (en) 2006-10-10 2017-02-21 Wyeth Purification of streptococcus pneumoniae type 3 polysaccharides
HUE039169T2 (hu) 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
US8540955B2 (en) 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
WO2010080486A2 (en) 2008-12-18 2010-07-15 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
EP2385981B1 (en) 2008-12-18 2019-09-04 Wyeth LLC Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
EP3626263A1 (en) 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
US20130273098A1 (en) 2010-12-10 2013-10-17 Jeffrey T. Blue Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2672053C2 (ru) 2012-12-20 2018-11-09 Пфайзер Инк. Способ гликоконъюгации
IL312327B2 (en) * 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
BR112016015835B1 (pt) * 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
FI3583947T3 (fi) * 2014-01-21 2023-10-12 Pfizer Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
AR104469A1 (es) 2014-08-08 2017-07-26 Glycovaxyn Ag Células huésped modificadas para su uso en producción de bioconjugados
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
IL259404B2 (en) 2015-11-17 2025-08-01 Pfizer Media and fermentation methods for producing polysaccharides in bacterial cell culture
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
IL267709B2 (en) * 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
WO2019050818A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
CN110392690B (zh) 2017-02-24 2024-01-30 默沙东有限责任公司 肺炎球菌缀合物疫苗制剂
US20200061542A1 (en) 2017-02-24 2020-02-27 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
WO2019036313A1 (en) 2017-08-16 2019-02-21 Merck Sharp & Dohme Corp. CONJUGATED PNEUMOCOCCAL VACCINE FORMULATIONS
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
HUE068482T2 (hu) * 2017-09-07 2025-01-28 Merck Sharp & Dohme Llc Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
CA3074706A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) * 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019083865A1 (en) 2017-10-25 2019-05-02 Merck Sharp & Dohme Corp. VACCINES WITH ADJUVANT
EP3720483B1 (en) 2017-12-06 2025-11-19 Merck Sharp & Dohme LLC Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
WO2019212846A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
EP3801469A4 (en) 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. CRITICAL LYOSPHERE REAGENTS KIT
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA3142692A1 (en) 2019-06-05 2020-12-10 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
MX2021014948A (es) 2019-06-05 2022-01-24 Merck Sharp & Dohme Llc Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.

Also Published As

Publication number Publication date
EP3589314A4 (en) 2021-04-21
US12295998B2 (en) 2025-05-13
JP2020514326A (ja) 2020-05-21
KR20190121330A (ko) 2019-10-25
MX2023001947A (es) 2023-03-14
JP7796163B2 (ja) 2026-01-08
US11090374B2 (en) 2021-08-17
MX2023001948A (es) 2023-03-14
AU2018225099B2 (en) 2024-08-22
WO2018156491A1 (en) 2018-08-30
JP7680185B2 (ja) 2025-05-20
MX2019009867A (es) 2019-10-02
JP2024112952A (ja) 2024-08-21
US20200054733A1 (en) 2020-02-20
JP2023036953A (ja) 2023-03-14
CA3050120A1 (en) 2018-08-30
US20210330778A1 (en) 2021-10-28
CN110337307A (zh) 2019-10-15
EP3589314A1 (en) 2020-01-08
US20240139303A1 (en) 2024-05-02
RU2019129503A3 (cg-RX-API-DMAC7.html) 2021-06-25
AU2018225099A1 (en) 2019-07-25
RU2019129503A (ru) 2021-03-24
US20210330777A1 (en) 2021-10-28
KR20240011879A (ko) 2024-01-26

Similar Documents

Publication Publication Date Title
US12295998B2 (en) Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US12016914B2 (en) Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102573200B1 (ko) 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질접합체를 포함하는 조성물 및 그의 사용 방법
BR112020004410A2 (pt) processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora
BR112020004502A2 (pt) polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
BR112020004509A2 (pt) polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
BR112020004396A2 (pt) polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
BR112019017390A2 (pt) Formulações de vacina pneumocócica conjugada e uso das mesmas
US20220218812A1 (en) Methods of treating patients with an immunogenic composition that protects against s. pneumoniae serotype 29
RU2774891C2 (ru) Повышение иммуногенности конъюгатов полисахарид streptococcus pneumoniae-белок
CA3123414C (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
BR122021023687B1 (pt) Usos de composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
EA048341B1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ КОНЪЮГАТЫ ПОЛИСАХАРИДА ИЗ Streptococcus pneumoniae И БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]